Thursday, July 28th, 2011
Is the third time the charm? This month the FDA approved Xeomin® (incobotulinumtoxinA) for the treatment of moderate to severe wrinkles in the glabellar region (frown lines). This is the third botulinum toxin to be approved by the FDA for cosmetic use (following Botox and Dysport). Merz Aesthetics plans to release Xeomin for use in the Spring of 2012.
So what’s so special about Xeomin? Will patients have better results from Xeomin than Botox?
I doubt it. Although I have not used the product and am not a Xeomin researcher, initial reports indicate that Xeomin does not need to be refrigerated like Botox and Dysport. While this is convenient for the plastic surgeon, it’s really of little consequence to the patient. However, with each vial of Botox costing most plastic surgeons well over $500, hopefully the emergence of Xeomin can help bring prices down for all of us.